<DOC>
	<DOCNO>NCT02472418</DOCNO>
	<brief_summary>Crossover study DFN15A versus DFN15B versus Placebo treatment migraine headache .</brief_summary>
	<brief_title>DFN15 Versus Placebo Patients With Migraine Headaches</brief_title>
	<detailed_description />
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>1 . Patients history episodic migraine ( defined International Classification Headache Disorders [ ICHD ] 228 ) experience average 2 6 migraine attack month past 12 month 14 headache day per month , least 48 hour headachefree time migraine attack ; 2 . Patients onset migraine without aura age 50 ; 3 . Patients migraine without aura , aura last longer 60 minute ; 4 . Patients report usual migraine pain 2 ( moderate ) 3 ( severe ) headache pain severity scale . 1 . Patients medication overuse headache ( MOH ) define ICHD228 : Opioids ≥ 10 day month 90 day prior screen Combination medication ( eg , Fiorinal® ≥ 10 day month ) Nonsteroidal antiinflammatory drug ( NSAIDs ) simple medication &gt; 14 day month 90 day prior screen Triptans ergots ≥ 10 day month 90 day prior screen 2 . Patients chronic warfarin sodium ; 3 . Patients take monoamine oxidaseA ( MAOA ) inhibitor ; 4 . Patients unstable dosage chronic medication 3 month prior screen , willing able maintain stable prestudy dose throughout study participation ; 5 . Patients 6 migraine attack month and/or 14 headache day month ( base upon patient selfreport ) ; 6 . Patients hemiplegic migraine migraine brain stem aura form neurologically complicate migraine ; 7 . Patients atypical aura ; 8 . Patients prolonged aura ( 1 hour ) . 9 . Patients history stroke transient ischemic attack ; 10 . Patients history migralepsy concurrent diagnosis seizure disorder ; 11 . Patients differentiate migraine headache tensiontype cluster headache nonmigraine headache ; 12 . Patients history 10 tensiontype headache per month ; 13 . Patients history cluster headache ; 14 . Patients diagnosis ICHD2 `` probable migraine '' ; 15 . Patients uncontrolled hypertension ( screen blood pressure ≥ 140/90 mmHg despite appropriate pharmacotherapy ) ; 16 . Patients severe renal impairment ( define serum creatinine &gt; 1.9 mg/dL ) ; 17 . Patients serum total bilirubin &gt; 1.9 mg/dL ; 18 . Patients serum aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatase &gt; 3 time upper limit normal ; 19 . Patients positive serology human immunodeficiency virus ( HIV ) , Hepatitis B surface antigen , Hepatitis C antibody . 20 . Patients history alcohol substance abuse ( include marijuana medical marijuana ) within 1 year would compromise data collection ; 21 . Patients history current neurological psychiatric impairment , cognitive dysfunction , opinion investigator , would compromise data collection ; 22 . Patients medical condition , judgment investigator medical monitor , would confound objective study ( eg , cancer history [ except basal cell carcinoma ] , systemic lupus erythematosus ) ; 23 . Patients participate clinical trial involve medication past 30 day 5 halflives study medication , whichever long</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>